Pediatrix Medical Group financials
$26.06+0.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B | $1.73B | $1.78B | $1.72B | $3.25B | $3.18B |
| Gross profit | $1.91B | $2.01B | $1.99B | $1.97B | $1.91B | $1.73B | $1.78B | $1.72B | $3.25B | $3.18B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $208.8M | -$59.0M | $7.3M | $172.7M | $195.6M | $98.1M | $171.8M | $248.4M | $454.9M | $571.7M |
| Net income | $165.4M | -$99.1M | -$60.4M | $66.3M | $131.0M | -$796.5M | -$1.50B | $268.6M | $320.4M | $324.9M |
| Net margin | 8.6% | −4.9% | −3.0% | 3.4% | 6.9% | −45.9% | −84.2% | 15.6% | 9.8% | 10.2% |
| Diluted EPS | $1.94 | $-1.19 | $-0.73 | $0.79 | $1.53 | $-9.55 | $-17.83 | $2.93 | $3.45 | $3.49 |
| EBITDA | $252.9M | $215.9M | $194.0M | $235.6M | $249.9M | $200.4M | $258.6M | $272.7M | $533.7M | $661.0M |
| Operating cash flow | $271.1M | $206.6M | $137.3M | $166.9M | $76.7M | $204.6M | $357.7M | $313.7M | $511.4M | $443.8M |
| Free cash flow | $252.6M | $184.6M | $104.0M | $137.2M | $44.5M | $175.8M | $338.4M | $296.6M | $485.2M | $404.5M |
| Diluted shares | 85.3M | 83.3M | 82.2M | 84.1M | 84.8M | 83.4M | 84.0M | 91.6M | 93.0M | 93.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $375.2M | $229.9M | $73.3M | $9.8M | $387.4M | $1.12B |
| Short-term investments | $124.5M | $118.6M | $104.5M | $93.2M | $99.7M | $104.9M |
| Total debt | $597.3M | $617.7M | $633.3M | $651.3M | $1.00B | $1.74B |
| Total assets | $2.25B | $2.15B | $2.22B | $2.35B | $2.72B | $3.35B |
| Total liabilities | $1.38B | $1.39B | $1.37B | $1.46B | $1.83B | $2.60B |
| Shareholders' equity | $865.9M | $764.9M | $849.1M | $891.6M | $896.7M | $747.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology